Vanda Pharmaceuticals Inc (VNDA)

06:12 AM

[EFFECT] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan

06:12 AM

May 04, 2026

Vanda Pharmaceuticals (VNDA) Launches Nereus for Motion Sickness Relief - GuruFocus

May 04, 2026

May 04, 2026

Vanda Pharmaceuticals shares rise on Nereus commercial launch By Investing.com - Investing.com Australia

May 04, 2026

May 04, 2026

Vanda Pharmaceuticals shares rise on Nereus commercial launch - Investing.com

May 04, 2026

May 04, 2026

D.C.'s Vanda Pharmaceuticals launches first new prescription motion sickness drug in decades - The Business Journals

May 04, 2026

May 04, 2026

Vanda launches motion sickness drug after 40-year gap By Investing.com - Investing.com South Africa

May 04, 2026

May 04, 2026

Vanda launches motion sickness drug after 40-year gap - Investing.com

May 04, 2026

May 04, 2026

Vanda Pharmaceuticals announces U.S. commercial availability of Nereus(TM) (tradipitant), the first new pharmacologic treatment for people with motion sickness in more than 40 years - marketscreener.com

May 04, 2026

May 04, 2026

Vanda Pharmaceuticals Announces U.S. Commercial Availability Of Nereus™ (Tradipitant), The First New Pharmacologic Treatment For People With Motion Sickness In More Than 40 Years - TradingView

May 04, 2026

May 03, 2026

Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com

May 03, 2026

May 02, 2026

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits

May 02, 2026

May 02, 2026

Vanda Pharmaceuticals (VNDA) Launches Nereus for Motion Sickness Prevention - GuruFocus

May 02, 2026

May 01, 2026

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years - The Malaysian Reserve

May 01, 2026

May 01, 2026

Vanda Pharmaceuticals (VNDA) Launches New Motion Sickness Drug, Stock Rises - GuruFocus

May 01, 2026

May 01, 2026

NEREUS now available for online purchase as Vanda Pharmaceuticals expands access - Traders Union

May 01, 2026

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

Apr 30, 2026

Gastroparesis Market: Investment-Ready Growth Trends to 2034 – DelveInsight | Vanda Pharma, Dr. Falk Pharma GmbH, Alfasigma S.p.A., PTC Therapeutics, CinDome Pharma - Barchart.com

Apr 30, 2026

Apr 30, 2026

Gastroparesis Market: Investment-Ready Growth Trends to 2034 - openPR.com

Apr 30, 2026

Apr 30, 2026

Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN

Apr 30, 2026

Apr 30, 2026

VNDA Stock Price, Quote & Chart | VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) - ChartMill

Apr 30, 2026

Apr 30, 2026

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - BioSpace

Apr 30, 2026

Apr 29, 2026

Vanda Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo

Apr 29, 2026

Apr 29, 2026

Vanda sets May 6 earnings release, investor call after market close - Stock Titan

Apr 29, 2026

Apr 29, 2026

BlackRock (NASDAQ: VNDA) reports 2.5M shares beneficially owned in 13G/A - Stock Titan

Apr 29, 2026

Apr 29, 2026

Vanda Pharmaceuticals (VNDA) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Apr 29, 2026

Apr 29, 2026

VNDA Q1'26 Earnings: revenue estimate is 54.98M USD - TradingView

Apr 29, 2026

Apr 29, 2026

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - The Malaysian Reserve

Apr 29, 2026

Apr 29, 2026

Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat

Apr 29, 2026

Apr 28, 2026

Vanda Pharmaceuticals Publishes Imsidolimab Research Findings - Intellectia AI

Apr 28, 2026

Apr 28, 2026

Vanda Sues FDA Over Suspended Drug Study for Stomach Disorder - Bloomberg Law News

Apr 28, 2026

Apr 28, 2026

Vanda Pharmaceuticals announces the publication of "Efficacy and - GuruFocus

Apr 28, 2026

Apr 27, 2026

Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Apr 27, 2026

Apr 27, 2026

The Christmas party is still ongoing in these stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell - MSN

Apr 27, 2026

Apr 27, 2026

Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN

Apr 27, 2026

Apr 27, 2026

HC Wainwright & Co. Reiterates Vanda Pharmaceuticals (VNDA) Buy Recommendation - MSN

Apr 27, 2026

Apr 26, 2026

Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia - MSN

Apr 26, 2026

Apr 24, 2026

Vanda Pharmaceuticals (VNDA) grants director 57,101 time-based RSUs - Stock Titan

Apr 24, 2026

Apr 24, 2026

Vanda Pharmaceuticals (NASDAQ: VNDA) director files initial Form 3 ownership - Stock Titan

Apr 24, 2026

Apr 24, 2026

Vanda Pharmaceuticals | DEFA14A: Others - Moomoo

Apr 24, 2026

Apr 24, 2026

Vanda Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo

Apr 24, 2026

Apr 23, 2026

[ARS] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan

Apr 23, 2026

Apr 23, 2026

Executive pay, board votes and pipeline in Vanda (NASDAQ: VNDA) 2026 proxy - Stock Titan

Apr 23, 2026

Apr 22, 2026

Vanda Pharmaceuticals adds Charles Duncan to board By Investing.com - Investing.com India

Apr 22, 2026

Apr 22, 2026

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board o - GuruFocus

Apr 22, 2026